ACP Letter to Senator Wyden regarding Principles for Drug Pricing Reform

Letter to Senator Wyden, Chair of the Senate Finance Committee, commending the release of the paper \"Principles for Drug Pricing Reform\" which includes recommendations for lawmakers when creating legislation to lower prescription drug costs.

Robin Chichester

Wyden, Drug Pricing Reform, Senate Finance Committee, prescription drug cost, Medicare Part D, Medicaid, copayment, drug price negotiation, Medicaid drug rebate program, drug rebates, transparency, drug formularies, product hopping, evergreening, pay-for-delay, data exclusivity, biosimilars, (S. 833), the Empowering Medicare Seniors to Negotiate Drug Prices Act of 2021, (S. 898),The FAIR Drug Pricing Act, (S 141) End Taxpayer Subsidies for Drug Ads Act

Fri, 07/02/2021 - 9:53 AM EDT

Fri, 07/02/2021 - 11:44 AM EDT

7

acp_letter_to_senator_wyden_regarding_principles_for_drug_pricing_reform_july_2021.pdf

{"Author":"Robin Chichester","CreationDate":"2021-07-02T09:53:30-04:00","Creator":"Microsoft\u00ae Word 2016","Keywords":"Wyden, Drug Pricing Reform, Senate Finance Committee, prescription drug cost, Medicare Part D, Medicaid, copayment, drug price negotiation, Medicaid drug rebate program, drug rebates, transparency, drug formularies, product hopping, evergreening, pay-for-delay, data exclusivity, biosimilars, (S. 833), the Empowering Medicare Seniors to Negotiate Drug Prices Act of 2021, (S. 898),The FAIR Drug Pricing Act , (S 141) End Taxpayer Subsidies for Drug Ads Act","ModDate":"2021-07-02T11:44:12-04:00","Producer":"Microsoft\u00ae Word 2016","Title":"ACP Letter to Senator Wyden regarding Principles for Drug Pricing Reform","Pages":7,"dc:format":"application\/pdf","dc:creator":"Robin Chichester","dc:title":"ACP Letter to Senator Wyden regarding Principles for Drug Pricing Reform","dc:subject":["Wyden","Drug Pricing Reform","Senate Finance Committee","prescription drug cost","Medicare Part D","Medicaid","copayment","drug price negotiation","Medicaid drug rebate program","drug rebates","transparency","drug formularies","product hopping","evergreening","pay-for-delay","data exclusivity","biosimilars","(S. 833)","the Empowering Medicare Seniors to Negotiate Drug Prices Act of 2021","(S. 898)","The FAIR Drug Pricing Act","(S 141) End Taxpayer Subsidies for Drug Ads Act"],"xmp:createdate":"2021-07-02T09:53:30-04:00","xmp:creatortool":"Microsoft\u00ae Word 2016","xmp:modifydate":"2021-07-02T11:44:12-04:00","xmp:metadatadate":"2021-07-02T11:44:12-04:00","pdf:producer":"Microsoft\u00ae Word 2016","pdf:keywords":"Wyden, Drug Pricing Reform, Senate Finance Committee, prescription drug cost, Medicare Part D, Medicaid, copayment, drug price negotiation, Medicaid drug rebate program, drug rebates, transparency, drug formularies, product hopping, evergreening, pay-for-delay, data exclusivity, biosimilars, (S. 833), the Empowering Medicare Seniors to Negotiate Drug Prices Act of 2021, (S. 898),The FAIR Drug Pricing Act , (S 141) End Taxpayer Subsidies for Drug Ads Act","xmpmm:documentid":"uuid:eea3147d-2475-4ef2-b530-e1fe64b03db9","xmpmm:instanceid":"uuid:e5e2b927-b4c1-4d78-9c01-0739695f2d21"}

2021